Integra LifeSciences (NASDAQ:IART) Given New $9.00 Price Target at Citigroup

Integra LifeSciences (NASDAQ:IART) had its price target cut by analysts at Citigroup from $11.00 to $9.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “sell” rating on the life sciences company’s stock. Citigroup’s price target would suggest a potential downside of 6.53% from the company’s previous close.

Several other brokerages have also commented on IART. Wall Street Zen lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a report on Monday, December 29th. Finally, Wells Fargo & Company dropped their price target on Integra LifeSciences from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday, February 27th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Integra LifeSciences presently has an average rating of “Reduce” and an average target price of $14.40.

Integra LifeSciences Stock Up 0.8%

IART stock traded up $0.08 during trading on Wednesday, hitting $9.63. 257,294 shares of the company’s stock were exchanged, compared to its average volume of 751,339. The business has a 50-day moving average price of $11.60 and a two-hundred day moving average price of $12.98. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $750.48 million, a price-to-earnings ratio of -1.43 and a beta of 1.02. Integra LifeSciences has a 52-week low of $9.17 and a 52-week high of $24.36.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.04. The company had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm’s revenue for the quarter was down 1.7% on a year-over-year basis. During the same quarter last year, the company earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, equities research analysts expect that Integra LifeSciences will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at approximately $25,000. GAMMA Investing LLC lifted its holdings in Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. boosted its position in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. EMC Capital Management acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth $75,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.